Navigation Links
Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer
Date:5/20/2008

Analysis Reveals Overall Survival Could be Extended if Patients Receive the

Most Effective Treatment Identified by ChemoFx

CHICAGO, May 20 /PRNewswire/ -- Precision Therapeutics Inc. announced today that the ChemoFx(R) Assay, a cell-based test that examines the response of a specific patient's tumor to various chemotherapies, correlates with significantly longer overall survival (OS) in patients with primary ovarian cancer. Patients who received a treatment determined by ChemoFx to lead to the best tumor response had an overall survival 1.4 times longer than those receiving a treatment shown by ChemoFx to be non-responsive.

Despite the fact that all patients had the same type of tumor, 88 percent of patients exhibited varying degrees of response to different agents when evaluated by the cell-based test. The analysis also found that nearly two-thirds of patients' tumors were more responsive to a treatment identified by ChemoFx, than to the treatment they actually received. Based on these results, a mathematical model was created to estimate survival had patients been treated with a drug that ChemoFx identified as more likely to result in a greater tumor response. The analysis found that median OS could be extended as much as 23 to 38 months.

"These overall survival data demonstrate that the responsiveness to treatment established by this sensitivity assay in the laboratory setting, may in fact translate into meaningful clinical outcomes for patients," said Thomas J. Herzog, MD, director of gynecologic oncology at the Columbia University Medical Center and lead investigator of the study. "If these results are confirmed in current ongoing trials, this will be a significant step towards establishing individualized treatment strategies for patients who will require chemotherapy."

About the Study

Patients analyzed in the study had stage II-IV primary epithelial ovarian cancer that was tested by ChemoFx between 1997 and 2003, and received at least one course of chemotherapy. The study evaluated differences in OS between patients who received treatment that was deemed responsive, intermediate-responsive or non-responsive based on ChemoFx test results.

Of the 206 patients analyzed:

-- Median OS of Assay non-responsive patients was 39.2 months

-- Median OS of Assay intermediate-responsive patients was 62.5 months

-- Median OS of Assay responsive patients was 80.4 months

When accounting for cancer stage and debulking -- the reduction of tumor size due to surgery or radiation treatment -- overall survival was significantly associated with the ChemoFx Assay and the cancer stage. In the model simulating improved survival if patients were treated with a therapy that caused a greater tumor response, median OS of patients treated with an Assay non-responsive drug could be improved from 39.2 to 62.5 months and median OS of patients treated with an Assay intermediate-responsive drug could be improved from 62.5 to 101.3 months.

"People with cancer often require additional treatment after receiving the standard of care chemotherapy. ChemoFx Assay can provide valuable information that could spare the patient from unnecessary toxicity associated with a potentially ineffective treatment," said Sean McDonald, CEO Precision Therapeutics. "The goal of ChemoFx is to empower patients and physicians with additional diagnostic information to help determine the most appropriate course of therapy for each individual patient."

This retrospective, multi-center analysis is a published abstract at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago and is available at http://www.asco.org.

About ChemoFx(R)

ChemoFx is a decision support tool that measures a specific patient's tumor response to various types, combinations and doses of chemotherapy selected by the patient's physician. The laboratory test examines how many cancer cells are killed after exposure to treatment, using a patient's living cancer cells that have been removed during a biopsy, aspiration or surgical procedure. ChemoFx can be used in primary, recurrent, and metastatic tumors.

ChemoFx can be tested in all solid tumor types, with ovarian and breast tumors being primarily tested. Other solid tumors most commonly tested include endometrial, colorectal, genitourinary, head and neck, lung, brain, pancreas, hepato-biliary.

About Precision Therapeutics

Precision Therapeutics is an oncology services company dedicated to the individualization of cancer therapy. Precision Therapeutics is a leader in the development and delivery of personalized treatment support tools that assist physicians and benefit cancer patients. For more information visit http://www.precisiontherapeutics.com, call 800-547-6165 or email info@ptilabs.com.


'/>"/>
SOURCE Precision Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
2. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
3. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
5. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
6. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
7. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Tumor Eradication Article Published by Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... Mass., May 10, 2017 Hologic, Inc. (Nasdaq: ... results for the fiscal second quarter ended April 1, ... of $1.84 increased 666.7% compared to the prior year ... resulted in a significant gain, while non-GAAP diluted EPS ... 3.2%, or 3.8% in constant currency terms.  Excluding the ...
(Date:5/10/2017)... May 10, 2017  The Corporate Whistleblower Center ... of sleep therapy clinics to call us anytime ... clinic is involved in a substantial scheme to ... hearing from an employee of a medical equipment ... scheme to provide medical practice groups with extra ...
(Date:5/10/2017)... 2017 CSSi, the global leader in patient ... industry, is proud to announce the launch of its ... features both enriched content and a customized layout that ... company,s already well-established position as the top global patient ... many months of hard work, we are delighted to ...
Breaking Medicine Technology:
(Date:5/27/2017)... (PRWEB) , ... May 27, 2017 , ... In any ... Regardless of the talent of your dental team at presenting treatment, there will always ... invest a lot of time and money on best practices when it comes to ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... ... met this week to review more than eighty-nine grant submissions all vying ... emerging young scientists in the Parkinson’s field.     , The American Parkinson Disease Association ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... ... integration of the CareFusion NOX-T3 portable sleep monitor with its Somnoware Sleep Device ... consistent, browser-based interface for diagnostic device operations. With this platform, initializing devices and ...
(Date:5/26/2017)... ... 26, 2017 , ... On May 24, the Congressional Budget Office (CBO) projected ... on May 4, would result in 23 million Americans losing their health insurance by ... Patient Protection and Affordable Care Act (ACA). , “It is clear from the ...
(Date:5/26/2017)... ... May 26, 2017 , ... Rob Lowe acts as host and helps ... series is on hiking in American. Viewers can reconnect with America as it explores ... hiking. , Many consumers have looked for an inventive new place for a family ...
Breaking Medicine News(10 mins):